Skip to content

uniQure QURE EBITDA margin

EBITDA margin at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-46.5%-1.0pp
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-1,759.7%+1,470pp
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-37,267.3%-37,310pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-572.1%-593pp
Precigen logo
PrecigenPGEN
-2,807.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
7.3%-34.5pp

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on trailing twelve months.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's EBITDA margin?
uniQure (QURE) reported EBITDA margin of -986.8% in Q1 2026.
How has uniQure's EBITDA margin changed year-over-year?
uniQure's EBITDA margin decreased by 28.7% year-over-year, from -766.6% to -986.8%.
What is the long-term trend for uniQure's EBITDA margin?
Over 5 years (2020 to 2025), uniQure's EBITDA margin has grown at a 28.2% compound annual growth rate (CAGR), from -306% to -1,059.7%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.